POTELIGEO 4 mg/ml, concentrate for solution for infusion bottle, 5 ml, CIP 3400955060406
Active ingredients: Mogamulizumab
Commercialized according to BDPMDispensing in France: Prescription only
Concentrate for solution for infusionbottle, 5 ml, CIP 3400955060406intraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- POTELIGEO 4 mg/mL, solution à diluer pour perfusion
- Pharmaceutical form
- solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon en verre de 5 mL
- Marketing authorisation holder
- KYOWA KIRIN HOLDINGS (PAYS-BAS)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 25 Feb 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62292771CIP75506040CIP133400955060406Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MOGAMULIZUMABsolution | 4 mg · 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.